Live Breaking News & Updates on Long Term Efficacy Of Deucravacitinib

Stay updated with breaking news from Long term efficacy of deucravacitinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Deucravacitinib Shows Superior Efficacy Over Placebo, Apremilast in Patients With Moderate to Severe Scalp Psoriasis

Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study.

....

United States , Journal Of The American Academy Dermatology , American Academy , Physician Global Assessment , Psoriasis Scalp Severity , Long Term Efficacy Of Deucravacitinib , Deucravacitinib Scalp Psoriasis Efficacy , Scalp Psoriasis Treatment Study , Moderate To Severe Psoriasis Response Rates , Deucravacitinib Vs Apremilast In Psoriasis ,